Abstract
Objective: To examine adverse outcomes associated with long-term opioid therapy (L-TOT) discontinuation among people with chronic non-cancer pain (CNCP). Design and setting: Population-based matched cohort study using UK Clinical Practice Research Datalink Aurum data. Population: L-TOT discontinuers were defined as individuals with opioid-free for >=180 days following an episode of L-TOT (>=3 opioid prescriptions within 90 days, or total >=90 supply days within the first year, excluding the initial 30 days) between 01/01/2000-31/12/2020. Main outcome measures: Propensity-score matched (1:5) cohorts of L-TOT discontinuers and L-TOT users were created to assess the association between L-TOT discontinuation and opioid-related death, hospitalisations due to bone fractures, their composite and all-cause mortality, using adjusted Cox regression models. If proportional hazards assumptions were violated, time-dependent Cox models were applied. Results: A total of 29,589 L-TOT discontinuers (female 60.04%, mean age 56.45+/-18.42 years) were identified and matched with L-TOT users. The median follow-up durations were 6.87 years (interquartile range: 3.32 to 11.51) for opioid-related death in L-TOT discontinuers, compared to 5.74 years (2.51 to 10.18) in L-TOT users. Similar follow-up durations were observed for hospitalisations due to bone fractures, the composite outcome, and all-cause mortality. After adjusting for covariates used in the propensity score models, L-TOT discontinuation was associated with a 37% reduced risk in opioid-related death (adjusted hazards ratio: 0.63, 95% confidence interval: 0.42 to 0.94), a 5% reduction in the risk of hospitalisations due to bone fractures (0.95, 0.91 to 0.99), a 7% reduced risk of the composite outcome (0.93, 0.87 to 0.97), and a 22% lower risk of all-cause mortality (0.78, 0.76 to 0.80). Conclusions: L-TOT discontinuation was associated with reduced risks of opioid-related death, hospitalisations due to bone fractures and all-cause mortality, suggesting important safety benefits of this practice. Further research should assess broader health outcomes beyond those examined in this study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The data access costs were fully supported by the NIHR (National Institute for Health and Care Research) Greater Manchester Patient Safety Research Collaboration. The funders had no role in study design, data collection, analysis, interpretation, writing, or the decision to submit the article. The views expressed are those of the authors and do not necessarily reflect those of the NIHR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Health Research Authority gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos